Clinical Trial Update: A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion [Phase 2, Phase 3]

View source ↗

Summary

This is a phase 2/3 clinical trial evaluating BMS-986504 plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy as first-line tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BMS-986504
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Metastatic Non-small Cell Lung Cancer With MTAP Deletion | Phase 2, Phase 3 | Status: RECRUITING